Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) had its price objective cut by analysts at Needham & Company LLC from $56.00 to $46.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 56.09% from the company’s current price.
Several other research analysts have also issued reports on the stock. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Finally, Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.60.
Check Out Our Latest Research Report on Collegium Pharmaceutical
Collegium Pharmaceutical Price Performance
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. During the same quarter last year, the firm posted $1.68 EPS. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. As a group, analysts expect that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.
Institutional Trading of Collegium Pharmaceutical
A number of institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in Collegium Pharmaceutical in the 2nd quarter worth $196,972,000. Rubric Capital Management LP lifted its position in shares of Collegium Pharmaceutical by 5.3% during the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after purchasing an additional 157,743 shares during the last quarter. Vanguard Group Inc. boosted its stake in Collegium Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after purchasing an additional 29,876 shares during the period. Janus Henderson Group PLC boosted its stake in Collegium Pharmaceutical by 26.0% during the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after purchasing an additional 377,073 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Collegium Pharmaceutical by 1.1% in the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock valued at $74,883,000 after buying an additional 18,160 shares during the last quarter.
Key Headlines Impacting Collegium Pharmaceutical
Here are the key news stories impacting Collegium Pharmaceutical this week:
- Positive Sentiment: Second-quarter adjusted EPS was $1.92, above analyst expectations of approximately $1.72, while revenue increased 6.3% year over year to $199.9 million. Adjusted EBITDA rose 8% to $113.8 million and operating cash flow was $71.3 million. Collegium Pharmaceutical Q2 Earnings Beat
- Positive Sentiment: The ADHD portfolio showed momentum: JORNAY PM revenue climbed 41% to $46.1 million, and the completed AZSTARYS acquisition contributed $12.9 million in partial-quarter revenue. Collegium raised its full-year AZSTARYS revenue outlook to $65 million-$75 million from $60 million-$70 million, potentially supporting longer-term growth. Collegium Q2 2026 Results
- Neutral Sentiment: Piper Sandler reaffirmed its “neutral” rating but lowered its price target to $43 from $45. Needham retained a “buy” rating while cutting its target to $46 from $56, reflecting continued upside but greater near-term caution. Analyst Price Target Updates
- Negative Sentiment: Collegium reduced full-year product-revenue guidance to $825 million-$855 million from $865 million-$895 million and lowered adjusted EBITDA guidance to $445 million-$470 million from $475 million-$500 million. The company cited lower pricing and weaker-than-expected authorized-generic Nucynta revenue.
- Negative Sentiment: The pain portfolio declined 9% year over year to $140.9 million; Nucynta revenue fell 24% and Xtampza ER revenue dropped 14%. GAAP results also shifted to a $15.1 million net loss from $12.0 million of net income, while operating expenses increased 45%, adding pressure to profitability. Collegium Sales and Guidance Report
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.
The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.
Featured Stories
- Five stocks we like better than Collegium Pharmaceutical
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
